Jun 06th 2012 - Edison Investment Research today published a report on Proteome Sciences (PRM.L, LSE:PRM, LON:PRM) entitled "Transformation Continues". In summary, the report says:
The benefits of Proteome Sciences’ new focus on commercialising its broad IP portfolio are coming through as underlying sales more than doubled in 2011. The continued launch of new products, such as SysQuant, and extra validation of its proprietary biomarkers should drive revenue growth over 200% in 2012. The value of Proteome Sciences’ technology was highlighted by the recent acquisition of Cellzome by GSK. Our valuation is unchanged at £127m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »